Respiratory Syncytial Virus Vaccine Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

A respiratory syncytial virus (RSV) vaccine is a medical preparation aimed at protecting individuals, especially infants, older adults, and high-risk groups, from severe respiratory infections caused by RSV. It works by stimulating the immune system to recognize and combat the virus, thereby reducing the likelihood of hospitalization and severe illness.

The main types of RSV vaccines include viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine is specifically designed to prevent infections caused by viruses. These vaccines have various indications, including pediatric, geriatric, and high-risk populations, and are distributed through hospitals, pharmacies, and government suppliers.

Tariffs are impacting the respiratory syncytial virus vaccine market by increasing costs of imported biologic raw materials, adjuvants, specialized packaging components, and cold-chain storage equipment required for vaccine production and distribution. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on globally sourced inputs, while Asia-Pacific faces cost pressures on export-oriented vaccine manufacturing. These tariffs are increasing production expenses and affecting pricing strategies for public immunization programs. However, they are also encouraging localized vaccine manufacturing, regional supply chain strengthening, and long-term investments in domestic biopharmaceutical infrastructure.

The respiratory syncytial virus vaccine market research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus vaccine market statistics, including respiratory syncytial virus vaccine industry global market size, regional shares, competitors with a respiratory syncytial virus vaccine market share, detailed respiratory syncytial virus vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus vaccine industry. This respiratory syncytial virus vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory syncytial virus vaccine market size has grown strongly in recent years. It will grow from $1378.59 million in 2025 to $1482.18 million in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising incidence of rsv-related hospitalizations, unmet medical need in infant immunization, increased awareness of respiratory viral infections, public health surveillance of seasonal rsv outbreaks, expansion of clinical trial activity.

The respiratory syncytial virus vaccine market size is expected to see strong growth in the next few years. It will grow to $1957.68 million in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing approval of novel rsv vaccines, growing government immunization funding, rising adoption among elderly populations, expansion of preventive healthcare programs, increasing focus on combination vaccine development. Major trends in the forecast period include increasing development of rsv vaccines for high-risk populations, rising focus on pediatric and geriatric immunization programs, growing investment in advanced vaccine formulations, expansion of hospital-based vaccination campaigns, enhanced emphasis on long-term rsv prevention.

The growing incidence of respiratory infections is expected to drive the expansion of the respiratory syncytial virus (RSV) vaccine market in the future. Respiratory infections, caused by viruses, bacteria, or other pathogens, affect the respiratory system, including the sinuses, throat, airways, or lungs. The increasing incidence of respiratory infections is influenced by factors such as air pollution, climate change, urbanization, aging populations, and the rise of drug-resistant pathogens. The RSV vaccine helps reduce the occurrence of respiratory infections by preventing RSV-related illnesses, particularly in vulnerable populations such as infants and older adults. For example, in October 2024, the UK Health Security Agency, a UK-based government body, reported a 10.7% year-over-year increase in tuberculosis (TB) cases in England in 2023, with cases rising from 4,380 in 2022 to 4,850. As a result, the growing incidence of respiratory infections will contribute to the growth of the RSV vaccine market.

Leading companies in the RSV vaccine market are focusing on developing innovative solutions, such as recombinant protein-based vaccine technologies, to meet the increasing demand for high-efficacy vaccines, improved immune protection, and safer formulations for older adults who are at greater risk of RSV-related complications. Recombinant protein-based vaccines are made using genetically engineered proteins that replicate viral components, enabling strong, targeted immune responses without the need for live viruses. This offers a more controlled and stable alternative to traditional vaccine approaches. For instance, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, received FDA approval for Arexvy, the first RSV vaccine aimed at preventing lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy uses advanced recombinant protein technology to target the RSV fusion (F) protein, a key viral component necessary for infection, offering robust protection for older adults.

In February 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Icosavax, Inc. for $1.1 billion. This acquisition strengthens AstraZeneca's vaccines and immune therapies pipeline, with Icosavax's lead candidate, IVX-A12, targeting RSV and human metapneumovirus (hMPV), two key pathogens responsible for severe respiratory infections in high-risk groups, including the elderly and individuals with chronic conditions. Icosavax, Inc. is a US-based clinical-stage biopharmaceutical company actively developing an RSV vaccine through its lead candidate, IVX-A12.

Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, Moderna Inc.

North America was the largest region in the respiratory syncytial virus vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the respiratory syncytial virus vaccine market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The respiratory syncytial virus vaccine market consists of sales of protein-based vaccines, mRNA vaccines, monoclonal antibodies, and live-attenuated vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Syncytial Virus Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses respiratory syncytial virus vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory syncytial virus vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The respiratory syncytial virus vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
• 2) By Clinical Indications: Pediatric Indication; Geriatric Indication; High-Risk Individuals
• 3) By Distribution Channel: Hospital And Others Pharmacies; Government Suppliers
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Moderna Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.